Articles By Anuja Singh
Could Servier’s $450M Fragile X Acquisition Redefine Its Neurology Strategy?
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
By
Will GSK’s Fluviral Supply Strengthen Canada’s Seasonal Flu Preparedness?
Key Highlights Public Health ImpactAnnual flu vaccination remains the most effective tool to reduce flu-related risks. Vulnerable populations…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine the Standard of Care in Narcolepsy…
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Is Abbott’s Dissolving Stent Set to Transform Peripheral Artery Disease Treatment in Europe?
Key Highlights A Breakthrough in PAD TreatmentAbbott has received CE Mark approval in Europe for its Esprit™ BTK…
Could the Medtronic–Abbott Partnership Shift the Future of Diabetes Technology as FDA Clears MiniMed™…
Key Highlights Expanding Integration Through Abbott PartnershipThe U.S. FDA has cleared Medtronic’s SmartGuard™ algorithm as an interoperable automated…
Could Servier’s $450M Fragile X Acquisition Redefine Its Neurology Strategy?
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
Will GSK’s Fluviral Supply Strengthen Canada’s Seasonal Flu Preparedness?
Key Highlights Public Health ImpactAnnual flu vaccination remains the most effective tool to reduce flu-related risks. Vulnerable populations…
Could Takeda’s Landmark Phase 3 Oveporexton Results Redefine the Standard of Care in Narcolepsy…
Key Highlights Clinical Breakthroughs Across EndpointsPatients treated with oveporexton demonstrated marked improvements in excessive daytime sleepiness, with most…
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Is Abbott’s Dissolving Stent Set to Transform Peripheral Artery Disease Treatment in Europe?
Key Highlights A Breakthrough in PAD TreatmentAbbott has received CE Mark approval in Europe for its Esprit™ BTK…
Could the Medtronic–Abbott Partnership Shift the Future of Diabetes Technology as FDA Clears MiniMed™…
Key Highlights Expanding Integration Through Abbott PartnershipThe U.S. FDA has cleared Medtronic’s SmartGuard™ algorithm as an interoperable automated…